Accelerated Progression of Hepatocellular Carcinoma during Immunosuppressive Therapy with Abatacept for Rheumatoid Arthritis

Satoshi Yoshiji, Ken Takahashi, Kenji Sawada, Masako Mishima, Yuji Eso, Masahiro Morita, Atsushi Takai, Hiroyuki Marusawa, Yoshihide Ueda, Tsuneyo Mimori and Hiroshi Seno

Abstract:
Abatacept, a cytotoxic T lymphocyte antigen-4 immunoglobulin recombinant fusion protein, is an immunosuppressive agent indicated for rheumatoid arthritis. Although no significant increase in malignancy has been reported in abatacept-treated patients, whether or not abatacept accelerates tumor progression in specific cancer types remains unclear. We herein report a 66-year-old woman who showed unusually rapid progression of hepatocellular carcinoma following abatacept therapy for rheumatoid arthritis. Abatacept was speculated to have accelerated her hepatocellular carcinoma progression in the setting of her preexisting risk factors: autoimmune hepatitis and long-term methotrexate use. We propose close tumor surveillance be performed during abatacept therapy, especially for high-risk patients.

Key words: hepatocellular carcinoma, cancer immunity, immunosuppressive therapy, abatacept, cytotoxic T lymphocyte antigen-4 (CTLA-4)

(Intern Med 58: 67-71, 2019)  
(DOI: 10.2169/internalmedicine.0843-18)

Introduction
Cytotoxic T lymphocyte antigen immunoglobulin-4 (CTLA-4) is one of the most studied checkpoint molecules that induce T-cell tolerance at the priming phase (1, 2). Strategies of targeting CTLA-4 have been clinically applied for controlling both autoimmune disease and cancer. Abatacept (a fusion protein of CTLA-4 and IgG1 Fc domain) and ipilimumab (anti-CTLA-4 antibody) are positive and negative modulators of the CTLA-4-mediated pathway, respectively; the former is indicated for rheumatoid arthritis (RA) and the latter for metastatic melanoma (3, 4). Despite no previous reports having described a significant increase in the risk for malignancy in association with abatacept (5-7), the immunosuppressive profile of abatacept should still be taken into account, especially for patients predisposed to cancer.

We herein report a case of accelerated progression of hepatocellular carcinoma (HCC) during immunosuppressive therapy with abatacept for RA and discuss the possible etiology of the present case.

Case Report
The patient was a 66-year-old woman with an 8-year history of RA and Sjögren’s syndrome. She had been treated with methotrexate (MTX) (4 mg/week) for 5 years and bucillamine (200 mg/day) for 4 years before she was referred to our department with abdominal distention at 65 years of age. She was diagnosed with liver cirrhosis classified as Child-Pugh class C (10 points). Laboratory tests revealed positive anti-nuclear antibodies (x84.7; normal range: <20) and elevated serum IgG levels (2,129 mg/dL; normal

1Department of Gastroenterology and Hepatology, Kyoto University Graduate School of Medicine, Japan and 2Department of Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine, Japan

Received: January 17, 2018; Accepted: March 6, 2018; Advance Publication by J-STAGE: August 24, 2018

Correspondence to Dr. Ken Takahashi, takaken@kuhp.kyoto-u.ac.jp
range: 820-1,840 mg/dL). Viral serology was negative for hepatitis B surface antigen (HBsAg), anti-hepatitis B surface antibody (anti-HBs), anti-hepatitis B core antibody (anti-HBc), and anti-hepatitis C virus antibody (anti-HCV). Neither alpha-fetoprotein (AFP) nor protein induced by vitamin K absence-II (PIVKA-II) levels were elevated. The values of liver function tests and tumor markers at the time of presentation are summarized in Table.

Since her liver function had already deteriorated before the administration of MTX (data not shown), autoimmune hepatitis rather than the long-term use of MTX was considered as the primary etiology of liver cirrhosis. However, MTX was speculated to be involved in the worsening of her progressive liver dysfunction.

An initial imaging evaluation of her liver by abdominal ultrasound (US) showed hepatic surface nodularity, atrophy of the right lobe, hypertrophy of the left lobe, and abdominal fluid retention. Although contrast-enhanced computed tomography (CE-CT) revealed a slightly hyperdense lesion at segment VIII in the arterial phase (Fig. 1A), HCC was not suspected at this point because of the absence of a washout appearance in the delayed phase of CE-CT and no detection of tumor by CE-US (not shown). We decided to carefully watch the lesion. Because of the inadequate control of RA-related joint pain, MTX and bucillamine were discontinued and replaced with abatacept (10 mg/kg, every 4 weeks). Abatacept markedly improved the patient’s joint pain and swelling. Six months after the administration of abatacept, however, CE-CT showed the progression of the above-mentioned hepatic lesion from 6 to 13 mm, which was clearly hyperdense in the arterial phase (Fig. 1B, upper panel) and hypodense in the delayed phase (Fig. 1B, middle panel). HCC was diagnosed, with confirmation made by CE-US (Fig. 1B, lower panel).

Radiofrequency ablation (RFA) was successfully performed. CE-CT performed three months after RFA confirmed no viable lesions (Fig. 2A). Six months later, however, follow-up CE-CT showed the marked recurrence of HCC near the ablated lesion (Fig. 2B). At this point, abatacept was discontinued due to the concern that it may have

**Table.** Laboratory Values at the Time of Presentation to Our Department.

| Variables                  | Present case | Normal range |
|----------------------------|--------------|--------------|
| PT (INR)                   | 1.70         | 0.8-1.2      |
| Albumin (g/dL)             | 2.3          | 3.9-5.1      |
| Total bilirubin (mg/dL)    | 2.0          | 0.3-1.3      |
| AST (IU/L)                 | 34           | 12-30        |
| ALT (IU/L)                 | 17           | 7-27         |
| γ-GTP (IU/L)               | 44           | 7-29         |
| ALP (IU/L)                 | 413          | 115-359      |
| AFP (ng/mL)                | 4.7          | <15          |
| PIVKA-II (mAU/mL)          | 16           | <40          |

PT: prothrombin time, AST: alanine aminotransferase, ALT: aspartate aminotransferase, γ-GTP: γ-glutamyltransferase, ALP: alkaline phosphatase, AFP: alpha-fetoprotein, PIVKA-II: protein induced by vitamin K absence or antagonist-II

**Figure 1.** Development of HCC after initiating abatacept therapy. (A) Initial CE-CT showed a slight hyperdense lesion at segment VIII in the arterial phase (arrow). (B) Six months after initiating abatacept therapy, CE-CT showed a 13-mm liver lesion at segment VIII, which was clearly hyperdense in the arterial phase (arrow in the upper panel) and hypodense in the delayed phase (arrow in the middle panel). Kupffer-phase imaging by CE-US showed the corresponding lesion as a hypoechogenic nodule (arrow in the lower panel). HCC: hepatocellular carcinoma, CE-CT: contrast-enhanced computed tomography, US: ultrasound
played a role in the progression of HCC. Transcatheter arterial chemoembolization (TACE) was performed (Fig. 2C). Two months later, the patient complained of exacerbated joint tenderness and swelling following the discontinuation of abatacept and strongly demanded that abatacept be resumed. After a careful discussion about the possible role of abatacept in the progression of HCC, abatacept was resumed to maximize her quality of life. One month after abatacept resumption, CT showed the unusually rapid progression of HCC, characterized by a diffusely growing viable lesion (Fig. 3A), aggressive invasion to intrahepatic portal vein

**Figure 2.** Early massive recurrence after RFA during continuation of abatacept. (A) Three months after RFA, CE-CT detected no recurrence (arrow). (B) Nine months after RFA, CE-CT revealed marked recurrence at the RFA site (arrow). (C) Hepatic arteriography demonstrated a large hypervascular tumor (arrow), a finding compatible with HCC recurrence. RFA: radiofrequency ablation, HCC: hepatocellular carcinoma

**Figure 3.** Rapid and aggressive progression of HCC. (A) Three months after TACE, CE-CT showed diffusely growing recurrent HCC (arrow). The black asterisk denotes a dense lipiodol deposit introduced by previous TACE. (B) Tumor invasion from the diffuse recurrent lesion to the intrahepatic portal vein was revealed by the same study (arrow). In both panels, massive ascites was demonstrated. HCC: hepatocellular carcinoma, TACE: transcatheter arterial chemoembolization

**Figure 4.** Serial changes in PIVKA-II in the present case. The PIVKA-II level increased parallel with HCC progression. PIVKA-II: protein induced by vitamin K absence-II, HCC: hepatocellular carcinoma
inflammation caused by autoimmune hepatitis. The long-term use of MTX may have contributed to the progression of liver damage and fibrosis, ultimately leading to cirrhosis. A strong immunosuppressive force driven by abatacept, combined with these predisposing factors, might accelerate the progression of HCC. Furthermore, because the immune environment of the liver is biased to tolerance (17), this inherent immunosuppressive property unique to the liver might also have an additive effect on abatacept.

Despite the limitations inherent to this single case report, we believe that our findings provide important information on the safety of abatacept for patients with underlying liver disease. During treatment with abatacept, close monitoring of the tumor and its progression should be considered, especially for the high-risk patients. The further accumulation of case reports is warranted to validate our observations and clarify the corresponding immunopathogenic mechanisms for HCC progression.

The authors state that they have no Conflict of Interest (COI).

References

1. Genovese MC, Becker JC, Schiff M, et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor α inhibition. New Engl J Med 353: 1114-1123, 2005.
2. Westhoven R, Robles M, Ximenes AC, et al. Clinical efficacy and safety of abatacept in methotrexate-naive patients with early rheumatoid arthritis and poor prognostic factors. Ann Rheum Dis 68: 1870-1877, 2009.
3. Gartlehner G, Hansen RA, Jonas BL, Thieda P, Lohr KN. The comparative efficacy and safety of biologics for the treatment of rheumatoid arthritis: a systematic review and metaanalysis. J Rheumatol 33: 2398-2408, 2006.
4. Lipson EF, Drake CG. Ipilimumab: an anti-CTLA-4 antibody for metastatic melanoma. Clin Cancer Res 17: 6958-6962, 2011.
5. Weinblatt M, Combe B, Covacci A, Aranda R, Becker JC, Keystone E. Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease modifying antirheumatic drugs: a one year randomized, placebo-controlled study. Arthritis Rheumatol 54: 2807-2816, 2006.
6. Kremer JM, Genant HK, Moreland LW, et al. Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial. Ann Intern Med 144: 865-876, 2006.
7. Simon TA, Snitzen AL, Franklin J, et al. Malignancies in the rheumatoid arthritis abatacept clinical development programme: an epidemiological assessment. Ann Rheum Dis 68: 1819-1826, 2009.
8. Koda M, Maeda Y, Matsunaga Y, et al. Hepatocellular carcinoma with sarcomatous change arising after radiofrequency ablation for well-differentiated hepatocellular carcinoma. Hepatol Res 27: 163-167, 2003.
9. Wegener’s GE. Etanercept plus standard therapy for Wegener’s granulomatosis. New Engl J Med 352: 351-361, 2005.
10. Duffy AG, Ulahannan SV, Makorova-Rusher O, et al. Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma. J Hepatol 66: 545-551, 2017.
11. Corcorran MA, Olson JM, Hecht C, Knezevich S, Vary JC. Erup- tive squamous cell carcinoma in a patient receiving abatacept for rheumatoid arthritis. J Am Acad Dermatol 69: e178-e179, 2013.
12. Olivo D, Grembiale RD, Tallarigo F, Russo E, De Sarro G, Ursini F. Kaposi’s sarcoma after T-cell costimulation blockade with
abatacept in rheumatoid arthritis: a case report. J Clin Pharm Ther 42: 367-369, 2017.
13. Deidda A, Pisanu C, Garau D, et al. Squamous cell carcinoma of the tongue following therapy of rheumatoid arthritis with abatacept. Clin Case Rep 2: 66-69, 2014.
14. Kumar A, Le DT. Hepatocellular carcinoma regression after cessation of immunosuppressive therapy. J Clin Oncol 34: e90-e92, 2014.
15. Shiina S, Teratani T, Obi S, et al. A randomized controlled trial of radiofrequency ablation with ethanol injection for small hepatocellular carcinoma. Gastroenterology 129: 122-130, 2005.
16. El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology 142: 1264-1273, 2012.
17. Crispe IN. Immune tolerance in liver disease. Hepatology 60: 2109-2117, 2014.

The Internal Medicine is an Open Access journal distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view the details of this license, please visit (https://creativecommons.org/licenses/by-nc-nd/4.0/).

© 2019 The Japanese Society of Internal Medicine
Intern Med 58: 67-71, 2019